T-cell receptor Vbeta gene usage by T cells reactive with the tumor-rejection antigen SART-1 in oral squamous cell carcinoma.

Int J Cancer 2004 Feb;108(5):686-95

Department of Oral and Maxillofacial Surgery, Graduate School of Dental Science, Kyushu University, Fukuoka, Japan.

We recently described that the SART-1(690-698) peptide could induce HLA-A24-restricted cytotoxic T lymphocytes (CTLs), which recognize the SART-1(259) (+) tumor cells from peripheral blood mononuclear cells (PBMCs) of HLA-A24(+) cancer patients. In our study, in 5 of 14 HLA-A24(+) patients with oral squamous cell carcinomas (SCCs), CTLs could be induced with the SART-1(690-698) peptide from the PBMCs. In 2 of the patients from whom the highest CTL activities were induced, the T-cell receptor (TCR) Vbeta repertoire expressed by the SART-1(690-698)-specific CTLs was found to be restricted and multiple Vbeta families were predominantly expressed in each patient. Although the predominant Vbeta families were different between the 2 patients, Vbeta7 was highly and commonly predominant. The same predominant Vbeta families were also detected in the tumor-infiltrating lymphocytes (TILs) from each patient, and each Vbeta family contained one or more unique T-cell clonotypes. The unique T-cell clonotypes were found to be common between the TILs and SART-1(690-698)-specific CTLs from each patient, and especially 2 T-cell clonotypes with Vbeta7 were identical even in the 2 patients. One of the 2 T-cell clonotypes with Vbeta7 was detected in the TILs from 11 of 14 HLA-A24(+) patients and another was found in those from 8 of HLA-A24(+) patients, while none of 10 HLA-A24(-) patients demonstrated both T-cell clonotypes. These results strongly suggest that the T-cell clonotypes with Vbeta7 are major TCR Vbeta genes expressed by SART-1(690-698)-specific CTLs. Furthermore, autologous tumor cells from one of the HLA-A24(+) patients stimulated the PBMCs and regional lymph node cells (LNCs) to expand the same T-cell clonotypes as those in the SART-1(690-698)-specific CTLs. These results strongly suggest that the SART-1(690-698)-specific CTLs clearly accumulate in vivo, especially in the TILs, as a consequence of in situ antigenic stimulation by autologous tumor cells. The identification of the unique TCR Vbeta genes used by SART-1(259)-specific CTLs should help to improve the diagnosis of the specific immune response in patients with SART-1(259) (+) cancers, especially during anticancer immunotherapy.

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.11591DOI Listing
February 2004
42 Reads

Publication Analysis

Top Keywords

t-cell clonotypes
28
sart-1690-698-specific ctls
20
hla-a24+ patients
16
vbeta families
12
tcr vbeta
12
clonotypes vbeta7
12
tumor cells
12
patients
10
t-cell
9
vbeta
8
squamous cell
8
oral squamous
8
ctls
8
t-cell receptor
8
unique t-cell
8
sart-1690-698 peptide
8
predominant vbeta
8
autologous tumor
8
vbeta genes
8
expressed sart-1690-698-specific
8

Altmetric Statistics

References

(Supplied by CrossRef)

Traversari et al.
J Exp Med 1992

Kawakami et al.
J Exp Med 1994

van der Bruggen et al.
Eur J Immunol 1994

Kang et al.
J Immunol 1995

Robbins et al.
J Immunol 1995

Marchand et al.
Int J Cancer 1995

Rosenberg et al.
Nat Med 1998

Nestle et al.
Nat Med 1998

Hiratsuka et al.
Cancer 1984

Mouri et al.
Cancer Immunol Immunother 1996

Nakao et al.
Cancer Res 1995

Similar Publications